Acurx Pharmaceuticals, Inc. (ACXP) News
Filter ACXP News Items
ACXP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ACXP News Highlights
- For ACXP, its 30 day story count is now at 4.
- Over the past 17 days, the trend for ACXP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest ACXP News From Around the Web
Below are the latest news stories about ACURX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ACXP as an investment opportunity.
New to The Street Signs Acurx Pharmaceuticals, Inc. to Additional Six-Month Media Contract with Iconic Billboard Ads and Commercial SupportNew to The Street Sign Acurx Pharmaceuticals, Inc. to Additional Six-Month Media Contract with Iconic Billboard Ads and Commercial Support FMW Media's business TV show, New to The Street, announces signing Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) ("Acurx") to an additional six-month media contract for filming and broadcasting tailored interviews, commercials, and digital billboard ads - https://www.acurxpharma.com/ & https://www.newtothestreet.com/ NEW YORK, March 23, 2023 (GLOBE NEWSW |
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2022 Earnings Call TranscriptAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2022 Earnings Call Transcript March 16, 2023 Operator: Greetings and welcome to the Acurx Pharmaceutical Fourth Quarter and Full Year 2022 Financial Results and Business Update. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Robert Shawah, Chief Financial Officer. Thank you, […] |
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business UpdateAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the fourth quarter and full year ended December 31, 2022. |
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Business UpdateAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its fourth quarter 2022 and fiscal year end 2022 financial results on Thursday, March 16, 2022, at 8:00 am ET before the U.S. financial markets open. |
Acurx is Setting a High Bar for New Treatments in C. diffA New Gold Standard for C. diff Therapy Could be in the Offing; |
CEO Spotlight: Acurx Pharmaceuticals CEO Confident His Phase 2b Ibezapolstat Drug Candidate Can Earn Front-Line Designation to Treat C. difficileAcurx Pharmaceuticals CEO David Luci tells Soulstring Media Group why he thinks his company and lead drug candidate, Ibezapolstat, can be a front-line treatment against C. difficile New York, New York--(Newsfile Corp. - February 7, 2023) - Soulstring Media Group, Llc., a market research, aggregator, and digital media production and management company specializing in creating and syndicating content from publicly traded and private companies, announced today that it had published an in-depth inte |
Presenting on the Emerging Growth Conference on January 25 Register NowMIAMI, Jan. 24, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 48th Emerging Growth Conference on January 25, 2022. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting companies |
Acurx Is Vying for Standard of Care in Treating Primary and Recurrent C. diffC. diff is a life-threatening bacterial infection that causes diarrhea and colitis, which is the inflammation of the colon. Approximately 600,000 are diagnosed with C. diff each year in the United ... |
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, is pleased to announce that it has been invited to present at the Emerging Growth Conference on January 25, 2023. This live, interactive online event will provide existing stockholders and the investment community with the opportunity to interact with the Company's President & Chief Executive Officer, |
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2022 Earnings Call TranscriptAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2022 Earnings Call Transcript November 14, 2022 Acurx Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.32 EPS, expectations were $-0.28. Operator: Greetings. Welcome to Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022. At this time, all participants are in a listen-only mode. […] |